San Diego based Santarus, a biopharmaceutical company, announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a FDA approved prescription drug to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.
According to the company, a 24-week, placebo-controlled, monotherapy study of the impact of CYCLOSET on glycemic control in 159 overweight adults (BMI ? 26.0 kg/m2 for males and ? 28.0 kg/m2 for females) with type 2 diabetes and baseline HbA1c of 7.5% – 11% indicated that once-daily morning dosing of CYCLOSET provided significant postprandial plasma glucose reductions throughout the day without increasing plasma insulin concentrations, and significantly improved HbA1c.